- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07540572
Un estudio para investigar la seguridad, farmacocinética y eficacia preliminar de la terapia IDE574 en participantes adultos con tumores sólidos avanzados
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: IDEAYA Clinical Trials
- Número de teléfono: +1-855-433-224
- Correo electrónico: IDEAYAClinicalTrials@ideayabio.com
Ubicaciones de estudio
-
-
California
-
Santa Monica, California, Estados Unidos, 90404-2095
- Activo, no reclutando
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510-3206
- Reclutamiento
- Yale School of Medicine - Cedar Street
-
Investigador principal:
- Patricia LoRusso, MD
-
Contacto:
- Karen Seely
- Número de teléfono: 203-314-3303
- Correo electrónico: karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation, Florida, Estados Unidos, 33322
- Reclutamiento
- Florida Clinical Trials Group
-
Investigador principal:
- Harshad Amin, MD
-
Contacto:
- Sandra Perez
- Número de teléfono: 772-297-3057
- Correo electrónico: perezs@floridactg.com
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322-1013
- Reclutamiento
- Winship Cancer Institute, Emory University
-
Investigador principal:
- Shipra Gandhi, MD
-
Contacto:
- Alejandra Bono
- Número de teléfono: 404-778-0954
- Correo electrónico: alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110-1010
- Reclutamiento
- Washington University - Siteman Cancer Center
-
Investigador principal:
- Faisal Fa'ak, MD
-
Contacto:
- Pamela Coe
- Número de teléfono: 314-747-7569
- Correo electrónico: mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Estados Unidos, 08816
- Reclutamiento
- START Astera, LLC
-
Investigador principal:
- Bruno Fang, MD
-
Contacto:
- Bruno S Fang
- Número de teléfono: 732-426-4750
- Correo electrónico: info@startresearch.com
-
-
New York
-
Lake Success, New York, Estados Unidos, 11042
- Reclutamiento
- START New York Long Island, LLC
-
Investigador principal:
- Geraldine O'Sullivan Coyne, MD
-
Contacto:
- Geraldine O'Sullivan Coyne
- Número de teléfono: 363-207-5160
- Correo electrónico: g.osullivancoyne@startresearch.com
-
New York, New York, Estados Unidos, 10032-3729
- Activo, no reclutando
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- SCRI Oncology Partners - PPDS
-
Investigador principal:
- Sarah Premji, MD
-
Contacto:
- Connor Frost
- Número de teléfono: 615-478-3475
- Correo electrónico: connor.frost@scri.com
-
-
Texas
-
Austin, Texas, Estados Unidos, 78758
- Reclutamiento
- NEXT Texas LLC - Austin
-
Investigador principal:
- Sheena Sahota, MD
-
Contacto:
- Heather Watson
- Número de teléfono: 737-610-5202
- Correo electrónico: nxtaus_coordinators@nextoncology.com
-
Dallas, Texas, Estados Unidos, 75039
- Reclutamiento
- NEXT Texas LLC - Dallas
-
Investigador principal:
- Faran Polani, MD
-
Contacto:
- Carmen Gonzalez
- Número de teléfono: 210-580-9479
- Correo electrónico: NXTDFW_Coordinators@nextoncology.com
-
Fort Worth, Texas, Estados Unidos, 76104
- Reclutamiento
- START Dallas Fort Worth, LLC
-
Investigador principal:
- Henry Xiong, MD
-
Contacto:
- Henry Xiong
- Número de teléfono: 682-350-3010
- Correo electrónico: info@startresearch.com
-
Houston, Texas, Estados Unidos, 77030-4009
- Reclutamiento
- MD Anderson Cancer Center
-
Investigador principal:
- Timothy Yap, MD
-
Contacto:
- Desirae Dufner
- Número de teléfono: 713-524-3434
- Correo electrónico: DDufner@mdanderson.org
-
Houston, Texas, Estados Unidos, 77054
- Reclutamiento
- NEXT Texas LLC - Houston
-
Investigador principal:
- Jennifer Segar, MD
-
Contacto:
- Carmen Gonzalez
- Número de teléfono: 210-580-9479
- Correo electrónico: nxthou_coordinators@nextoncology.com
-
San Antonio, Texas, Estados Unidos, 78229
- Reclutamiento
- NEXT Texas LLC - San Antonio
-
Investigador principal:
- David Sommerhalder, MD
-
Contacto:
- April Guerra
- Número de teléfono: 210-580-9500
- Correo electrónico: NXTSA_Coordinators@nextoncology.com
-
San Antonio, Texas, Estados Unidos, 78229
- Reclutamiento
- Start San Antonio, LLC
-
Investigador principal:
- Amita Patnaik, MD
-
Contacto:
- Hector Navarro
- Número de teléfono: 210-593-5700
- Correo electrónico: Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City, Utah, Estados Unidos, 84119
- Reclutamiento
- START Mountain Region, LLC
-
Investigador principal:
- William McKean, MD
-
Contacto:
- William B McKean
- Número de teléfono: 1 (801) 907-4750
- Correo electrónico: info@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- NEXT Virginia
-
Investigador principal:
- Mohamad Salkeni, MD
-
Contacto:
- Maybelle De La Rosa
- Número de teléfono: 703-783-4518
- Correo electrónico: nxtvir_coordinators@nextoncology.com
-
-
-
-
K'alak'i T'bilisi
-
Batumi, K'alak'i T'bilisi, Georgia, 6000
- Reclutamiento
- High Technology Hospital MedCenter Ltd
-
Investigador principal:
- Tamta Makharadze, MD
-
Contacto:
- Mamuka Sikharulidze
- Número de teléfono: +995 568 999 559
- Correo electrónico: sikharulidzemamuka3@gmail.com
-
Tbilisi, K'alak'i T'bilisi, Georgia, 114
- Reclutamiento
- Pineo Medical Ecosystem
-
Contacto:
- Nino Kekenadze
- Número de teléfono: +995 593 660 940
- Correo electrónico: Nkekenadze@pineo.ge
-
Investigador principal:
- Mziuri Zakaraia, MD
-
Tbilisi, K'alak'i T'bilisi, Georgia, 112
- Activo, no reclutando
- LLC ARENSIA Exploratory Medicine
-
Tbilisi, K'alak'i T'bilisi, Georgia, 144
- Activo, no reclutando
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi, K'alak'i T'bilisi, Georgia, 186
- Activo, no reclutando
- LLC Caucasus Medical Centre
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
Experimental: Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
Experimental: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
Experimental: Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Periodo de tiempo: Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Periodo de tiempo: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Periodo de tiempo: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Periodo de tiempo: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Periodo de tiempo: total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Periodo de tiempo: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Periodo de tiempo: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Periodo de tiempo: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Periodo de tiempo: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Periodo de tiempo: total study duration
|
total study duration
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IDE574-001
- 178299 (Otro identificador: Regulatory Agency Identifier Number (s))
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .